Rhumbline Advisers reduced its stake in shares of SIGA Technologies, Inc. (OTCMKTS:SIGA) by 3.4% during the 1st quarter, Holdings Channel reports. The firm owned 64,884 shares of the biotechnology company’s stock after selling 2,305 shares during the quarter. Rhumbline Advisers’ holdings in SIGA Technologies were worth $390,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new stake in SIGA Technologies in the first quarter worth $79,000. AltraVue Capital LLC acquired a new stake in SIGA Technologies in the fourth quarter worth $16,014,000. ClariVest Asset Management LLC acquired a new stake in SIGA Technologies in the fourth quarter worth $144,000. Vanguard Group Inc. raised its holdings in SIGA Technologies by 8.7% in the third quarter. Vanguard Group Inc. now owns 2,117,841 shares of the biotechnology company’s stock worth $14,592,000 after purchasing an additional 170,001 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its holdings in SIGA Technologies by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 25,841 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 20,182 shares during the period. 6.66% of the stock is currently owned by institutional investors and hedge funds.
Separately, TheStreet lowered shares of SIGA Technologies from a “b” rating to a “c+” rating in a report on Friday, May 10th.
Shares of SIGA opened at $5.30 on Thursday. SIGA Technologies, Inc. has a one year low of $4.68 and a one year high of $8.47.
SIGA Technologies (OTCMKTS:SIGA) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.02) earnings per share for the quarter. The business had revenue of $10.46 million for the quarter.
In related news, Director James Antal sold 30,000 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $5.70, for a total transaction of $171,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Dennis E. Hruby sold 50,000 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $5.61, for a total transaction of $280,500.00. The disclosure for this sale can be found here. Corporate insiders own 4.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/06/13/siga-technologies-inc-otcmktssiga-shares-sold-by-rhumbline-advisers.html.
SIGA Technologies Company Profile
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Recommended Story: What does an outperform rating mean?
Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.